Research
Metabolic adaptation
KN069 led to significant metabolic improvements including lower fasting glucose and triglycerides.
KN069 may improve metabolic health markers in this population.
StrongSupportsmedium confidence
Metabolic improvements included lower fasting glucose, triglycerides, uric acid and elevated insulin/C-peptide.
Why this rating
Based on the randomized, double-blind trial design.
Source
A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of <scp>KN069</scp> (a Dual <scp>GLP</scp> ‐ <scp>1R</scp> Agonist and <scp>GIPR</scp> Antagonist) in Male Adults With Overweight or Obesity
Jinlian Xie et al. · Diabetes Obesity and Metabolism · 2026
rct · n=48
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →